

**Complete if Known**

<b>Application Number</b>	10/697,563
<b>Filing Date</b>	October 31, 2003
<b>First Named Inventor</b>	GUTHRIE
<b>Art Unit</b>	NOT YET SPECIFIED
<b>Examiner Name</b>	NOT YET SPECIFIED
<b>Attorney Docket Number</b>	T00462-0003-WO-US

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/697,563	
			Filing Date	October 31, 2003	
			First Named Inventor	GUTHRIE	
			Art Unit	NOT YET SPECIFIED	
			Examiner Name	NOT YET SPECIFIED	
Sheet	2	of	2	Attorney Docket Number	T00462-0003-WO-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
W		ROBBINS, Effect of Flavonoids on Survival Time of Rats Fed Thombogenic or Atherogenic Regimens, Journal of Atherosclerosis Research, volume 7, 1967, pages 3-10, Elsevier Publishing Company, The Netherlands.	
		GUTHRIE et al, In Vitro Studies on Anti-Cancer and Cholesterol-Lowering Activities of Citrus Flavonoids and Ilinonoids", FASEB Journal, March 15, 2000, page A564: Abstract, vol. 14, Federation of American Societies for Experimental Biology, Bethesda, MD, USA.	
		KUROWSKA et al, Regulation of Lipoprotein Metabolism in HEPG2 Cells by Citrus Flavonoids", American Chemical Society, abstract, March 2000, vol. 219, The National Meeting, American Chemical Society, Washington, D.C., USA.	
		KUROWSKA et al, Hypolipidemic activities of tangeretin a flavonoid from tangerine in vitro and in vivo, Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001, March 31-April 4, 2001, Abstract, Orlando, Florida, USA.	
		KUROWSKA et al., Tangeretin, a Citrus Flavonoid, reduces metabolic abnormalities associated with insulin resistance, FASEB Journal, March 20, 2002, page A648: Abstract, volume 16, Federation of American Societies for Experimental Biology, Bethesda, MD, USA.	
W		MERCK RESEARCH LABORATORIES, The Merck Manual of Diagnosis and Therapy, 1999, page 166 right-hand column, page 167 left-hand column line 4, Merck Research Laboratories, Whitehouse Station, N.J., USA.	

Examiner Signature	<i>W. Waddell</i>	Date Considered	2-22-05
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.